Managing Director Kyle J. Heppenstall, has released his latest position paper and, according to the paper, drug development costs have risen 145% since 2003, but in a contrarian statement that might surprise many he states, “Consumers are getting a good deal.”

CompassX Managing Partner, Kyle J. Heppenstall, recently spoke about deploying improvements to the FDA’s drug approval process which are getting a significant amount of attention. His presentation analyzed the recent improvements made by the FDA’s Center for Drug Evaluation and Research (CDER), but also reveals that further improvements can be achieved. According to Heppenstall, “This doesn’t mean the FDA can stop moving forward. A formal operational excellence study can produce significant return on investment for the FDA and the health of U.S. citizens.”

Newly issued guidance by the Supreme Court has the potential to reshape the landscape of biologic drug and product commercialization, says Kyle J. Heppenstall, Managing Director of CompassX Consulting, a consultancy focused on architecting and executing strategies for healthcare and regulated industries.